Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 2Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 45Carcinoma, Renal Cell 19Neoplasm Metastasis 16Leukemia, Myeloid, Acute 15Kidney Neoplasms 14Skin Neoplasms 11Neoplasms 10Leukemia 7Breast Neoplasms 7Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Ovarian Neoplasms 4Neuroblastoma 4Congenital Abnormalities 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Uveal Melanoma 2Prostatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1

Interventions

Rituximab 130Cyclophosphamide 113Peripheral Blood Stem Cell Transplantation 59fludarabine phosphate 55Etoposide 47Mycophenolic Acid 44Radiotherapy 41Filgrastim 41Tacrolimus 40Whole-Body Irradiation 36Busulfan 34Melphalan 33Cyclosporine 30Cytarabine 29Methotrexate 28sargramostim 27Vincristine 27Antilymphocyte Serum 27Prednisone 26Lenalidomide 23obinutuzumab 22Doxorubicin 22Carmustine 21Bortezomib 20Methylprednisolone 19fludarabine 17Dexamethasone 17Bendamustine Hydrochloride 17ibritumomab tiuxetan 15Cord Blood Stem Cell Transplantation 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Follicular × Interleukin-2 × Clear all
NCT00100737 2006-02-06

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Chiron Corporation

Phase 2 Terminated
300 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡